In Ireland, 948 medicines price cuts now delivering 78 million euros savings, IPHA confirms
The new pricing Agreement between the Irish Pharmaceutical Healthcare Association (IPHA) and the State which was finalized in July, is on course to save the State over 140 million euros ($154 million) in its first year.
Following an analysis of the 948 separate product price changes as listed by the Health Services Executive (HSE), the IPHA is confirming the annual total value of the price reductions since August 1 across all of the IPHA products is on track to provide savings of 78.4 million euros annually.
These reductions are due to price realignments and off-patent products facing competition. In addition, an estimated 65 million euros in rebates payable by IPHA members to the HSE would bring the total IPHA saving to the State to over 140 million euros in the first 12 month period of the Agreement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze